PMID: 6103390May 17, 1980Paper

The place of bone-marrow transplantation in acute myelogenous leukaemia

Lancet
R L PowlesT J McElwain

Abstract

28 patients with acute myeloid leukaemia (AML) in first remission were maintained on chemotherapy, consisting of courses of cytosine arabinoside and daunorubicin, and immunotherapy with irradiated AML cells and BCG. The relapse rate and survival rate of these patients were compared with those of a simultaneously treated group of 22 patients in first remission who received sibling bone-marrow transplants after cyclophosphamide (60 mg/kg) given for 2 days and followed by a single dose of 1000 rads total body irradiation. Substantially fewer transplanted patients (4 out of 22) than chemo-immunotherapy patients (19 out of 28) relapsed (p less than 0.005) and 14 (64%) transplanted patients remain alive, well, and disease-free. Survival curves of the two groups of patients show that the transplanted patients never fared worse than the chemo-immunotherapy patients. We suggest that when possible young AML patients in remission should be offered transplantation as an alternative form of treatment.

References

Oct 1, 1970·Blood·E D Thomas, R Storb

❮ Previous
Next ❯

Citations

Jul 1, 1981·Journal of Clinical Immunology·E D Thomas
Nov 15, 1984·Klinische Wochenschrift·P OstendorfD Niethammer
May 1, 1982·Indian Journal of Pediatrics·S StorchR P Gale
Jul 26, 1980·Lancet·C J StoddardA G Johnson
Jul 26, 1980·Lancet·R L Powles, G Morgenstern
Oct 1, 1983·Clinics in Haematology·R Storb, G W Santos
Aug 28, 1980·The New England Journal of Medicine·H J WeinsteinE Frei
Sep 4, 1980·The New England Journal of Medicine·J A HansenE R Giblett
Jun 18, 1981·The New England Journal of Medicine·P L WeidenUNKNOWN Seattle Marrow Transplant Team
Jul 9, 1981·The New England Journal of Medicine·P A OillL B Guze
Jun 23, 1983·The New England Journal of Medicine·E D Thomas, F Hutchinson
Jun 1, 1982·British Journal of Haematology·R D Barr, J A McBride
Oct 11, 1980·British Medical Journal·J A Whittaker
May 2, 1981·British Medical Journal·N P LucieA G Smith
Nov 7, 1981·British Medical Journal·J M Goldman
Jun 1, 1982·Gut·M J FarthingT J McElwain
May 1, 1983·Journal of Clinical Pathology·J P SloaneP J Dady
Mar 1, 1981·Postgraduate Medical Journal·D SamsonC D Reid
Jun 1, 1984·British Journal of Haematology·H J DeegE D Thomas
Jan 1, 1984·Cancer Investigation·K M Sullivan, R Storb
May 1, 1989·British Journal of Haematology·A Butturini, R P Gale
Mar 1, 1984·British Journal of Haematology·A M Worsley, D A Galton
Jan 1, 1987·Annals of the New York Academy of Sciences·R Champlin, R P Gale
Nov 1, 1982·The American Journal of Medicine·C A SklarN K Ramsay
Nov 1, 1984·European Journal of Cancer & Clinical Oncology·G L Floersheim
Jan 1, 1986·Current Problems in Cancer·M M Bortin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.